$RPRX
Royalty Pharma plc Stock $rprx

$rprx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000180276824000012 Filed on February 15, 2024

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$596.1M	$536.3M	$2.355B
YoY Change	5.36%	-6.48%	5.24%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$59.19M	$57.20M	$249.7M
YoY Change	-19.18%	12.84%	9.87%
% of Gross Profit
Research & Development	$500.0K	$50.50M	$52.00M
YoY Change	-99.01%	98.04%	-70.64%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	-$16.83M	$50.50M	$52.00M
YoY Change	-103.89%	98.04%	-70.64%
Operating Profit		$151.4M	$1.492B
YoY Change		-21.21%	385.94%
Interest Expense	$123.0M	$46.03M	$187.2M
YoY Change	-197.46%	-2.01%	-0.41%
% of Operating Profit		30.4%	12.54%
Other Income/Expense, Net	-$18.31M	-$29.37M	$207.9M
YoY Change	1471.5%	-204.12%	-370.05%
Pretax Income	$717.6M	$122.1M	$1.700B
YoY Change	-217.63%	-44.61%	638.96%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%	0.0%	0.0%
Net Earnings	$494.3M	$72.11M	$1.135B
YoY Change	-208.39%	-49.45%	2549.5%
Net Earnings / Revenue	82.93%	13.45%	48.2%
Basic Earnings Per Share		$0.16	$2.54
Diluted Earnings Per Share	$0.82	$0.16	$2.53
COMMON SHARES
Basic Shares Outstanding		448.4M shares	447.6M shares
Diluted Shares Outstanding		601.1M shares	602.9M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$495.3M	$941.7M	$1.234B
YoY Change	-71.07%	-32.78%	-49.18%
Cash & Equivalents	$477.0M	$936.4M	$477.0M
Short-Term Investments	$18.30M	$5.300M	$756.7M
Other Short-Term Assets	$3.798M	$6.784M	$3.798M
YoY Change	-95.8%	-92.51%	-95.8%
Inventory
Prepaid Expenses
Receivables	$14.24M	$16.00M	$14.24M
Other Receivables	$22.40M	$22.00M	$22.40M
Total Short-Term Assets	$1.274B	$1.729B	$1.274B
YoY Change	-50.13%	-26.19%	-50.13%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$375.9M	$378.3M	$15.10B
YoY Change	-5.36%	-7.7%	6.13%
Other Assets	$6.522M	$20.21M	$6.522M
YoY Change	-77.99%	-33.98%	-77.99%
Total Long-Term Assets	$15.11B	$14.13B	$15.11B
YoY Change	5.96%	-7.85%	5.96%
TOTAL ASSETS
Total Short-Term Assets	$1.274B	$1.729B	$1.274B
Total Long-Term Assets	$15.11B	$14.13B	$15.11B
Total Assets	$16.38B	$15.86B	$16.38B
YoY Change	-2.57%	-10.28%	-2.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.17M	$14.00M	$15.17M
YoY Change	91.82%	-13.11%	91.82%
Accrued Expenses	$51.68M	$13.00M	$51.68M
YoY Change	-4.58%	-1.51%	-4.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Total Short-Term Liabilities	$161.4M	$127.9M	$161.4M
YoY Change	-86.17%	-88.69%	-86.17%
LONG-TERM LIABILITIES
Long-Term Debt	$6.135B	$6.131B	$6.135B
YoY Change	0.27%	0.27%	0.27%
Other Long-Term Liabilities	$900.0K	$11.00M	$900.0K
YoY Change	-64.0%	11.11%	-64.0%
Total Long-Term Liabilities	$6.136B	$6.131B	$6.136B
YoY Change	0.24%	0.27%	0.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$161.4M	$127.9M	$161.4M
Total Long-Term Liabilities	$6.136B	$6.131B	$6.136B
Total Liabilities	$6.298B	$6.270B	$9.855B
YoY Change	-13.59%	-13.59%	-11.89%
SHAREHOLDERS EQUITY
Retained Earnings	$2.518B	$2.135B
YoY Change	28.14%	-14.78%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.629M	$2.624M
YoY Change	-6.31%	-5.88%
Treasury Stock Shares
Shareholders Equity	$6.526B	$6.139B	$6.526B
YoY Change
Total Liabilities & Shareholders Equity	$16.38B	$15.86B	$16.38B
YoY Change	-2.57%	-10.28%	-2.57%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	$494.3M	$72.11M	$1.135B
YoY Change	-208.39%	-49.45%	2549.5%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Operating Activities	$772.6M	$573.5M	$2.988B
YoY Change	35.56%	6.43%	39.36%
INVESTING ACTIVITIES
Capital Expenditures	$1.002B	$451.1M	$2.116B
YoY Change	300.5%	-134.27%	21.47%
Acquisitions
YoY Change
Other Investing Activities	$2.033M	$500.0K	$2.038M
YoY Change	-99.69%	-100.46%	-99.71%
Cash From Investing Activities	-$1.000B	-$450.6M	-$2.073B
YoY Change	-341.16%	-68.38%	101.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$304.8M
YoY Change
Debt Paid & Issued, Net		$1.000B
YoY Change
Cash From Financing Activities	-231.9M	-1.360B	-$2.149B
YoY Change	-12.69%	490.87%	127.42%
NET CHANGE
Cash From Operating Activities	772.6M	573.5M	$2.988B
Cash From Investing Activities	-1.000B	-450.6M	-$2.073B
Cash From Financing Activities	-231.9M	-1.360B	-$2.149B
Net Change In Cash	-459.4M	-1.237B	-$1.234B
YoY Change	-163.89%	10.77%	-827.0%
FREE CASH FLOW
Cash From Operating Activities	$772.6M	$573.5M	$2.988B
Capital Expenditures	$1.002B	$451.1M	$2.116B
Free Cash Flow	-$229.6M	$122.4M	$872.3M
YoY Change	-171.83%	-93.4%	116.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Interest Expense InterestExpense	187187000	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-2290000	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	96610000	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	87139000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-33442000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-48066000	usd
CY2023	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	230840000	usd
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-6815000	usd
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	17859000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	78335000	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	53535000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5678000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001802768
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Derivative Asset Current Statement Of Financial Position Extensible Enumeration DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherAssetsCurrent
CY2022Q4	us-gaap	Derivative Asset Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39329
CY2023	dei	Entity Registrant Name EntityRegistrantName	Royalty Pharma plc
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1535773
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	110 East 59th Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
CY2023	dei	City Area Code CityAreaCode	212
CY2023	dei	Local Phone Number LocalPhoneNumber	883-0200
CY2023	dei	Security12b Title Security12bTitle	Class A ordinary shares, par value $0.0001
CY2023	dei	Trading Symbol TradingSymbol	RPRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	13700000000	usd
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	477010000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1710751000	usd
CY2023Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	0	usd
CY2022Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	24421000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	738438000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	691319000	usd
CY2023Q4	rprx	Accrued Royalty Receivable AccruedRoyaltyReceivable	14242000	usd
CY2022Q4	rprx	Accrued Royalty Receivable AccruedRoyaltyReceivable	16830000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	18300000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1300000	usd
CY2023Q4	rprx	Other Royalty Income Receivable Current OtherRoyaltyIncomeReceivableCurrent	22405000	usd
CY2022Q4	rprx	Other Royalty Income Receivable Current OtherRoyaltyIncomeReceivableCurrent	19767000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3798000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	90520000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1274193000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2554908000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	14088655000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	13493106000	usd
CY2023Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	199487000	usd
CY2022Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	112348000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	437100000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	226300000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	375894000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	397175000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6522000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29629000	usd
CY2023Q4	us-gaap	Assets Assets	16381851000	usd
CY2022Q4	us-gaap	Assets Assets	16813466000	usd
CY2023Q4	rprx	Distributions Payable To Legacy Non Controlling Interests Current DistributionsPayableToLegacyNonControllingInterestsCurrent	83155000	usd
CY2022Q4	rprx	Distributions Payable To Legacy Non Controlling Interests Current DistributionsPayableToLegacyNonControllingInterestsCurrent	94803000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	15165000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7906000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	51682000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	54162000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	997512000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11375000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12400000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	161377000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1166783000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6135285000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6118810000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	900000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2500000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6297562000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7288093000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	rprx	Deferred Shares Par Or Stated Value Per Share DeferredSharesParOrStatedValuePerShare	0.000001
CY2023Q4	rprx	Deferred Shares Par Or Stated Value Per Share DeferredSharesParOrStatedValuePerShare	0.000001
CY2023Q4	rprx	Deferred Shares Shares Outstanding DeferredSharesSharesOutstanding	384640000	shares
CY2023Q4	rprx	Deferred Shares Shares Issued DeferredSharesSharesIssued	384640000	shares
CY2022Q4	rprx	Deferred Shares Shares Outstanding DeferredSharesSharesOutstanding	371325000	shares
CY2022Q4	rprx	Deferred Shares Shares Issued DeferredSharesSharesIssued	371325000	shares
CY2023Q4	rprx	Deferred Shares Value Issued DeferredSharesValueIssued	0	usd
CY2022Q4	rprx	Deferred Shares Value Issued DeferredSharesValueIssued	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4011435000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3666160000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2517583000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1964689000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	3557792000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	3897223000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2629000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2806000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10084289000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9525373000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16381851000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16813466000	usd
CY2023	us-gaap	Revenues Revenues	2354554000	usd
CY2022	us-gaap	Revenues Revenues	2237215000	usd
CY2021	us-gaap	Revenues Revenues	2289463000	usd
CY2023	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	560656000	usd
CY2022	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	904244000	usd
CY2021	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	452842000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52000000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	177106000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	200084000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5670000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22996000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	249748000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	227303000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	182826000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	615827000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	862404000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	1930150000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	858748000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	1492150000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	307065000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1430715000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	28882000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8973000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-19490000	usd
CY2022	us-gaap	Interest Expense InterestExpense	187961000	usd
CY2021	us-gaap	Interest Expense InterestExpense	166142000	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-21532000	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	72291000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21737000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14755000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	207938000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77001000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-189514000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1700088000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	230064000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1241201000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Profit Loss ProfitLoss	1700088000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	230064000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	565254000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	187232000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	621473000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1134834000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	42832000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	619728000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.49
CY2023	us-gaap	Profit Loss ProfitLoss	1700088000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	230064000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	1241201000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	24000000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11600000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	53432000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	50896000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-29432000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-39296000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1700088000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	200632000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1201905000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	565254000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	175418000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	604323000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1134834000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25214000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	597582000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9895815000	usd
CY2021	rprx	Noncontrolling Interest Increase From Contributions NoncontrollingInterestIncreaseFromContributions	48539000	usd
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	614973000	usd
CY2021	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.68
CY2021	us-gaap	Dividends Cash DividendsCash	285184000	usd
CY2021	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2443000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	1241201000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11600000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	50896000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10248545000	usd
CY2022	rprx	Noncontrolling Interest Increase From Contributions NoncontrollingInterestIncreaseFromContributions	11596000	usd
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	604248000	usd
CY2022	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.76
CY2022	us-gaap	Dividends Cash DividendsCash	333322000	usd
CY2022	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2170000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	230064000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	24000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	53432000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9525373000	usd
CY2023	rprx	Noncontrolling Interest Increase From Contributions NoncontrollingInterestIncreaseFromContributions	11855000	usd
CY2023	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	487721000	usd
CY2023	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.80
CY2023	us-gaap	Dividends Cash DividendsCash	358327000	usd
CY2023	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2357000	usd
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	9846000	shares
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	304759000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	1700088000	usd
CY2023	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	4577000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10084289000	usd
CY2023	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	3201410000	usd
CY2022	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	2507236000	usd
CY2021	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	2315854000	usd
CY2023	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	1302000	usd
CY2022	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	72943000	usd
CY2021	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	151158000	usd
CY2023	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	158843000	usd
CY2022	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	69891000	usd
CY2021	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	44123000	usd
CY2023	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	18823000	usd
CY2022	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	39142000	usd
CY2021	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	34384000	usd
CY2023	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	71604000	usd
CY2022	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	24982000	usd
CY2021	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	3135000	usd
CY2023	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	0	usd
CY2022	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	0	usd
CY2021	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	34660000	usd
CY2023	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	0	usd
CY2022	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	0	usd
CY2021	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	34660000	usd
CY2023	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	0	usd
CY2022	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	0	usd
CY2021	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	16093000	usd
CY2023	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	2000000	usd
CY2022	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	2106000	usd
CY2021	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	6876000	usd
CY2023	rprx	Payments For Upfront Development Stage Funding PaymentsForUpfrontDevelopmentStageFunding	50000000	usd
CY2022	rprx	Payments For Upfront Development Stage Funding PaymentsForUpfrontDevelopmentStageFunding	175000000	usd
CY2021	rprx	Payments For Upfront Development Stage Funding PaymentsForUpfrontDevelopmentStageFunding	193208000	usd
CY2023	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	243012000	usd
CY2022	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	222969000	usd
CY2021	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	184511000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	169168000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	170139000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	130430000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2987802000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2143980000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2017536000	usd
CY2023	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	43882000	usd
CY2022	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	usd
CY2021	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	523000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	12542000	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	9896000	usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	34855000	usd
CY2023	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	0	usd
CY2022	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	87785000	usd
CY2021	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	135134000	usd
CY2023	rprx	Proceeds From Issuance Of Equity Securities Fnni ProceedsFromIssuanceOfEquitySecuritiesFNNI	0	usd
CY2022	rprx	Proceeds From Issuance Of Equity Securities Fnni ProceedsFromIssuanceOfEquitySecuritiesFNNI	211158000	usd
CY2021	rprx	Proceeds From Issuance Of Equity Securities Fnni ProceedsFromIssuanceOfEquitySecuritiesFNNI	115957000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	479559000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	70441000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1440000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	542044000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	62500000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	234869000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1196579000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	24391000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	792341000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1597851000	usd
CY2023	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	2115522000	usd
CY2022	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	1741640000	usd
CY2021	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	2191502000	usd
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	21215000	usd
CY2021	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2023	rprx	Payments For Milestones PaymentsForMilestones	12400000	usd
CY2022	rprx	Payments For Milestones PaymentsForMilestones	0	usd
CY2021	rprx	Payments For Milestones PaymentsForMilestones	18600000	usd
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2038000	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2072789000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1029421000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1870280000	usd
CY2023	rprx	Payments To Noncontrolling Interests Royalty Receipts PaymentsToNoncontrollingInterestsRoyaltyReceipts	376987000	usd
CY2022	rprx	Payments To Noncontrolling Interests Royalty Receipts PaymentsToNoncontrollingInterestsRoyaltyReceipts	441963000	usd
CY2021	rprx	Payments To Noncontrolling Interests Royalty Receipts PaymentsToNoncontrollingInterestsRoyaltyReceipts	479604000	usd
CY2023	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	0	usd
CY2022	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	31301000	usd
CY2021	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	20367000	usd
CY2023	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	119534000	usd
CY2021	rprx	Payment Of Dividends To Shareholders PaymentOfDividendsToShareholders	285184000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	543000	usd
CY2022	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	1059000	usd
CY2021	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	7339000	usd
CY2023	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	6933000	usd
CY2022	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	6133000	usd
CY2021	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	36874000	usd
CY2023	rprx	Cash Acquired In Connection With Purchase Of Non Controlling Interest CashAcquiredInConnectionWithPurchaseOfNonControllingInterest	4973000	usd
CY2022	rprx	Cash Acquired In Connection With Purchase Of Non Controlling Interest CashAcquiredInConnectionWithPurchaseOfNonControllingInterest	0	usd
CY2021	rprx	Cash Acquired In Connection With Purchase Of Non Controlling Interest CashAcquiredInConnectionWithPurchaseOfNonControllingInterest	0	usd
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	350000000	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2023	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	350000000	usd
CY2022	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	usd
CY2021	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	usd
CY2023	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1000000000	usd
CY2022	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	usd
CY2021	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1272533000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1596000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1347000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	13046000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2148754000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-944856000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	385112000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1233741000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	169703000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	532368000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1710751000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1541048000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1008680000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	477010000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1710751000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1541048000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div>
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	454500000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of December 31, 2023 and 2022 were held with Bank of America, State Street, Scotiabank, Citibank, TD Bank, DNB Bank and U.S. Bank. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, GSK, Roche, Johnson & Johnson, Biogen, AbbVie, Astellas, Novartis, Pfizer and Gilead. As of December 31, 2023 and 2022, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 31% of our current portion of financial royalty assets, respectively, and represented the largest individual marketer and payor of our royalties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant credit losses with respect to the collection of income or revenue on our royalty assets.</span></div>
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q4	rprx	Common Stock Exchange Ratio CommonStockExchangeRatio	1
CY2022Q1	rprx	Long Term Funding Partnership Amount LongTermFundingPartnershipAmount	300000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Number Of Tranches LongTermFundingPartnershipNumberOfTranches	5	tranche
CY2022Q1	rprx	Long Term Funding Partnership Initial Payment LongTermFundingPartnershipInitialPayment	50000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Additional Payments Aggregate Amount LongTermFundingPartnershipAdditionalPaymentsAggregateAmount	200000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Optional Amount Unavailable LongTermFundingPartnershipOptionalAmountUnavailable	75000000	usd
CY2022Q1	rprx	Long Term Funding Partnership Installment Repayments Amount Drawn Multiple LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple	1.9
CY2022Q1	rprx	Long Term Funding Partnership Interest Free And Payment Free Period Number Of Calendar Quarters Tranche Two LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo	34	quarter
CY2023	rprx	Long Term Funding Partnership Expected Payment LongTermFundingPartnershipExpectedPayment	175000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	352367000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	102133000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	454500000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	18300000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	437100000	usd
CY2023Q4	rprx	Debt Securities Available For Sale Liability Noncurrent DebtSecuritiesAvailableForSaleLiabilityNoncurrent	900000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	350000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	124900000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	225100000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1300000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	226300000	usd
CY2022Q4	rprx	Debt Securities Available For Sale Liability Noncurrent DebtSecuritiesAvailableForSaleLiabilityNoncurrent	2500000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	225100000	usd
CY2021Q2	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	600000000	usd
CY2021Q3	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	16100000	usd
CY2022	rprx	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	fair value
CY2023	rprx	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	fair value
CY2023	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	87100000	usd
CY2022	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	-39100000	usd
CY2021	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	-41400000	usd
CY2023Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	17892238000	usd
CY2023Q4	rprx	Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows	2927438000	usd
CY2023Q4	rprx	Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows	14964800000	usd
CY2023Q4	rprx	Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal	137707000	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	14827093000	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	14800000000	usd
CY2023Q4	rprx	Unapproved Financial Assets Held At Costs UnapprovedFinancialAssetsHeldAtCosts	562300000	usd
CY2022Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	16776307000	usd
CY2022Q4	rprx	Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows	2476460000	usd
CY2022Q4	rprx	Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows	14299847000	usd
CY2022Q4	rprx	Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal	115422000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	14184425000	usd
CY2020Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	1263824000	usd
CY2021	rprx	Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense	912710000	usd
CY2021	rprx	Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense	446955000	usd
CY2021	rprx	Financing Receivable Change In Present Value Write Off Cumulative Allowance FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance	21721000	usd
CY2021	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-12913000	usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	1694945000	usd
CY2022	rprx	Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense	1394679000	usd
CY2022	rprx	Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense	296637000	usd
CY2022	rprx	Financing Receivable Change In Present Value Write Off Cumulative Allowance FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance	5723000	usd
CY2022	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	1584000	usd
CY2022	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-193798000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	2591882000	usd
CY2023	rprx	Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense	1006933000	usd
CY2023	rprx	Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense	468562000	usd
CY2023	rprx	Financing Receivable Change In Present Value Write Off Cumulative Allowance FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance	87393000	usd
CY2023	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	22285000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	3065145000	usd
CY2020	rprx	Financing Receivable Allowance For Credit Loss Financial Royalty Asset Writeoff FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff	-323700000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52000000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	177100000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	200100000	usd
CY2021	rprx	Research And Development Expense Upfront Payment And Premium Paid ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid	193200000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	164715000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	183678000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	7116322000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	997512000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6118810000	usd
CY2023Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1000000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	164700000	usd
CY2023Q4	rprx	Number Of Classes Of Voting Stock NumberOfClassesOfVotingStock	2	class
CY2023Q4	rprx	Common Stock Voting Rights Number Of Votes CommonStockVotingRightsNumberOfVotes	1	vote
CY2023Q4	rprx	Common Stock Quarterly Conversion Basis CommonStockQuarterlyConversionBasis	1
CY2023	rprx	Share Based Compensation Arrangement By Share Based Payment Award Covenant Percentage Of Net Economic Profit ShareBasedCompensationArrangementByShareBasedPaymentAwardCovenantPercentageOfNetEconomicProfit	0.20
CY2023Q3	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.20
CY2023Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.20
CY2023Q4	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.20
CY2023Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.20
CY2023	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	358300000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P1Y
CY2023	us-gaap	Profit Loss ProfitLoss	1700088000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1134834000	usd
CY2023	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	392726000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1527560000	usd
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	602900000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.54
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.53
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	42832000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	42832000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	619728000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	619728000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	437963000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	414794000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	437972000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	414802000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.49
CY2023	us-gaap	Profit Loss ProfitLoss	1700088000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	230064000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	1241201000	usd
CY2023	rprx	Increase Decrease In Financial Royalty Assets IncreaseDecreaseInFinancialRoyaltyAssets	2197754000	usd
CY2022	rprx	Increase Decrease In Financial Royalty Assets IncreaseDecreaseInFinancialRoyaltyAssets	2125096000	usd
CY2021	rprx	Increase Decrease In Financial Royalty Assets IncreaseDecreaseInFinancialRoyaltyAssets	2065083000	usd
CY2023	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	560656000	usd
CY2022	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	904244000	usd
CY2021	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	452842000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5670000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22996000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	20499000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	21356000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	20162000	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-2290000	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	96610000	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-21532000	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	87139000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-33442000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-48066000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	28882000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8973000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-19490000	usd
CY2023	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	18823000	usd
CY2022	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	39142000	usd
CY2021	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	34384000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-419000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-358000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2357000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2170000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2443000	usd
CY2023	rprx	Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss	0	usd
CY2022	rprx	Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss	53432000	usd
CY2021	rprx	Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss	50896000	usd
CY2023	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	230840000	usd
CY2022	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-6815000	usd
CY2021	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	17859000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	615827000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	rprx	Gain Loss On Derivative Financial Instruments GainLossOnDerivativeFinancialInstruments	0	usd
CY2022	rprx	Gain Loss On Derivative Financial Instruments GainLossOnDerivativeFinancialInstruments	0	usd
CY2021	rprx	Gain Loss On Derivative Financial Instruments GainLossOnDerivativeFinancialInstruments	16093000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-20912000	usd
CY2021	rprx	Increase Decrease In Cash Collections On Financing Receivables IncreaseDecreaseInCashCollectionsOnFinancingReceivables	2315854000	usd
CY2023	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	-2588000	usd
CY2022	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	-36456000	usd
CY2021	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	20131000	usd
CY2023	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	1521000	usd
CY2022	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	4744000	usd
CY2021	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	9012000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-559000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2198000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1857000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6236000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2286000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4586000	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-2480000	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-3534000	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	15550000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2987802000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2143980000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2017536000	usd
CY2023	rprx	Milestone Payment Accrued But Not Paid MilestonePaymentAccruedButNotPaid	0	usd
CY2022	rprx	Milestone Payment Accrued But Not Paid MilestonePaymentAccruedButNotPaid	12400000	usd
CY2021	rprx	Milestone Payment Accrued But Not Paid MilestonePaymentAccruedButNotPaid	0	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	11375000	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	usd
CY2023Q4	rprx	Distributions Payable To Legacy Non Controlling Interests Current DistributionsPayableToLegacyNonControllingInterestsCurrent	83155000	usd
CY2022Q4	rprx	Distributions Payable To Legacy Non Controlling Interests Current DistributionsPayableToLegacyNonControllingInterestsCurrent	94803000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001802768-24-000012-index-headers.html	Edgar Link	pending
0001802768-24-000012-index.html	Edgar Link	pending
0001802768-24-000012.txt	Edgar Link	pending
0001802768-24-000012-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rprx-20231231.htm	Edgar Link	pending
rprx-20231231.xsd	Edgar Link	pending
rprx-20231231ex1021.htm	Edgar Link	pending
rprx-20231231ex211.htm	Edgar Link	pending
rprx-20231231ex231.htm	Edgar Link	pending
rprx-20231231ex311.htm	Edgar Link	pending
rprx-20231231ex312.htm	Edgar Link	pending
rprx-20231231ex32.htm	Edgar Link	pending
rprx-20231231ex42.htm	Edgar Link	pending
rprx-20231231ex971.htm	Edgar Link	pending
rprx-20231231_g1.jpg	Edgar Link	pending
rprx-20231231_g2.jpg	Edgar Link	pending
rprx-20231231_g3.jpg	Edgar Link	pending
rprx-20231231_g4.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
rprx-20231231_cal.xml	Edgar Link	unprocessable
rprx-20231231_lab.xml	Edgar Link	unprocessable
rprx-20231231_pre.xml	Edgar Link	unprocessable
rprx-20231231_def.xml	Edgar Link	unprocessable
rprx-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RPRX
Royalty Pharma plc Stock $rprx

2023 Q4 Form 10-K Financial Statement

#000180276824000012 Filed on February 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RPRX Royalty Pharma plc Stock $rprx

2023 Q4 Form 10-K Financial Statement

#000180276824000012 Filed on February 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RPRX
Royalty Pharma plc Stock $rprx